Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer

Virchows Archiv

Volumn 427, Issue 5, 1996, Pages 487-496

  Ito, Hiroshi ^a   Yonemura, Yutaka ^a   Fujita, Hidcto ^a   Tsuchihara, Kazuya ^a   Kawamura, Taiichi ^a   Nojima, Naonii ^a   Fujimura, Takashi ^a   Nose, Hiroshi ^a   Endo, Voshio ^a   Sasaki, Takuma ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 2; Urokinase type plasminogen activator

Indexed keywords

MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROPIDIUM IODIDE; UROKINASE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER SURGERY; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOPLASM; EMBRYO; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOLOGY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLOIDIES; PROGNOSIS; STOMACH NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029548924     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00199509     Document Type: Article

References (66)

1. Astedt B, Lecander I, Ny T (1987) The placenta! type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1: 203-208
2. Blasi F, Vassalli J-D, Dan0 K (1987) Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104: 801-804
3. Booth NA, Simpson AJ, Croll A, Benne» B, MacGregor R (1988) Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70: 327-333
4. Cajoy J, Kruithof EKO, Schleuning WD, Sordat B, Bachman F (1986) Plasminogen activators, plasminogen activator inhibitors and procoagulant analysis in twenty human tumor cell lines. Int J Cancer 38:719-727 -4-x.
5. Chucholowski N, Schmitt M, Goretzki L, Schuren E, Moniwa N, Weidi U, Kramer M, Wagner B, Janicke F, Graeff H (1992) Flow cytometry in tumor cell receptor analysis. Surgery of the ' literature and recent developments concerning the urokinasetype plasminogen activator (uPA). Biochem Soc Trans 20: 208-216
6. CoIIen D (1991) On the regulation and control of fibrinolysis. Semin Thromb Hemost 17: 231-239
7. Cubellis MV, Wun T, Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085
8. Dan0 K, Anderson PA, Grondahl-Hansen J, Krisensen PI, Nielsen IS, Skiver L (1985) Plasminogen activators, tissue degradation and cancer. Ad v Cancer Res 44: 139-226
9. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, Ingh HF van den (1988) Plasminogen activator profiles in neoplastic tissues of human colon. Cancer Res 48: 4520-4524
10. Duffy MJ, Reilly D, O'SulIivan C, O'Higgins N, Fennelly JJ, Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
11. Fidler U, Gersten DW, Hart I (1978) The biology of cancer invasion and metastasis. Ad v Cancer Res 28: 149-250
12. Foekens JA, Schmitt MS, Putten WLJ van, Peters HA, Bontenbal M, Janicke F, et al (1992) Prognostic value of urokinasetype plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
13. Grondahl-Hansen J, Christensen I.J, Rosenquist C, Brunner N, Mouridsen H.T, Dan0 K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
14. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A (1992) The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873
15. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335
16. Hekman CM, Loskutoff DJ (1987) Fibrinolytic pathway and the endothelium. Semin Thromb Hemost 13: 514-527
17. Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dedocyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202
18. Inokuchi K, Kodama Y, Sasaki O, Kamagawa T, Okamura T (1983) Differentiation of growth patterns of early gastric carcinoma determined by cytophotometric DNA analysis. Cancer 51:1138-1141
19. Janicke F, Schmitt M, Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312
20. Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. JpnJSurgll: 127-139
21. Jin L, Nakajima M, Nicolson GL (1990) Immunochemical localization of heparanase in mouse and human melanomas. Int J Cancer 45: 1088-1095
22. Kallionirme O, Punnonen R, Mattila J, Lehtinen M, Koivula T (1988) Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian carcinoma. Cancer 61: 334339
23. Kawanishi H, Tanaka K, Takai S, Takada H, Yamamura M, Hioki K, Nagura H, Yamamoto M (1991) Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics. J Surg Oncol 46: 246-256
24. Kawano T, Mormoto K, Uemura Y (1970) Parietal pulification and properties of urokinase inhibitor from human placenta. J Biochem 67: 333-342
25. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH, et al (1988) Regulation of mRNAs for type1 plasminogen activator inhibitor, fibronectine, and type-1 procollagen by transforming growth factor-β. J Biol Chern 263: 3111-3115
26. Keski-Oja J, Kori K, Lohi J, Laiho M (1991) Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemost 17: 231-239
27. Kimura H, Yonemura Y (1991) Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer 67: 2588-2593
28. Kirchheimer JC, Pflüger H, Ritschl P, Hienert G, Binder BR (1985) Plasminogen activator activity in bone métastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5: 344-355
29. Kohga S, Harvey SR, Weaver RM, Markus G (1985) Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787-1796
30. Kristensen P, Pyke C, Lund LR, Andreasen PA, Dan0 K (1990) Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93: 559-566
31. Kruithof EKO (1988) Plasminogen activator inhibitors - a review. Enzyme 40: 113-121
32. Kruithof EKO, Gudinchet A, Bachmann F (1988) Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 59: 7-12
33. Laiho M, Keski-Oja J (1989) Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49: 2533-2553
34. Liotta LA (1986) Tumor invasion and metastasis - role of the extracellular matrix. Cancer Res 46: 1-7
35. Liotta LA, Goldfarb RH, Brundage R, Siegel GP, Terranova V, Garbisa S (1981) Effect of plasminogen activator (urokinase), Plasmin, and thrombin on glycoprotein and collagenous compounds of basement membrane. Cancer Res 41: 4629-4636
36. Liotta LA, Thorgereisson UP, Garbias S (1982) Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1: 277-297
37. Loskutoff DJ, Sawdey M, Mimuro J (1989) Type 1 plasminogen activator inhibitor. In: Coller BS (ed) Progress in hemostasis and thrombosis, vol 9. Saunders, New York, pp 87-115
38. Markus G, Takita H, Camiolo SM, Corasanti JG, Evers JL, Hobika GH (1980) Content1 and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 40: 841-848
39. Nakamura M, Konno H, Tanaka T, Maruo T, Nishino N, Aoki K, et al (1992) Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65: 709-719
40. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Backer K, Roder JD, Fink U, Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
41. Oka T, Ishida T, Nishino T, Sugimachi K (1991) Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 51: 3522-3525
42. Olson D, Pollanen J, H0yer-Hansen G, Rönne E, Sakaguchi K, Wun TC, et al (1992) Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133
43. Ossowski L, Reich E (1983) Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 50: 527-535
44. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dan0 K (1991) The plasminogen activation system iri human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51: 4067-4071
45. Pyke C, Kristensen P, Ralfkiaer E, Gr<,ndahl-Hansen J, Erisken J, Blasi F, et al (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138:1059-1067
46. Quax PHA, Van-Leeuwen RTJ, Verspaget HW, Verheijen JH (1990) Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 50: 1488-1494
47. Reilly D, Christensen L, Duch M, Molan N, Duffy MJ, Andreasen PA (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214
48. Rijken DC, Wijngaards G, Welbergen J (1981) Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 97: 477-486
49. Rochefort H, Capony F, Garcia M (1982) Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev 1:277-297
50. Saito K, Nagashima M, Iwata M, Hamada H, Sumiyoshi K, Takada Y, et al (1990) The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 58: 355-366
51. Saksela O, Rifkin DB (1988) Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 4: 93-126
52. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K (1982) Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells - role in metastasis. Int J Cancer 30: 669-673
53. Sappino AP, Busso N, Belin D, Vassali JD (1987) Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 47: 4043-41046
54. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y (1986) The AMeX method. Am J Pathol 125: 431-435
55. Schwanz GK, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP (1994) Defining the invasive phenotype of proximal gastric cancer cells. Cancer 73: 22-27
56. Sier CFM, Verspager HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW (1993) Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 34: 80-85
57. Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69: 381-387
58. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S (1992) Plasminogen activator system in human breast cancer. Int J Cancer 50: 345-348
59. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, et al (1991) Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 48: 20-27
60. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O (1991) Plasminogen activator inhibitor in human carcinoma tissues. Int J Cancer 48: 481-484
61. Tissot J-D, Hauert J, Bachmann F (1984) Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 34: 295-302
62. Tryggvason K, Hoyhtya M, Salo T (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochim BiophysActa907: 191-217
63. Umehara Y, Kimura T, Yoshida N, Oba N, Harada Y (1991) Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol 30: 527-535
64. Verspaget HW, Verheijen JH, de Bruin PAF, Griffioen G, Lamers CBHW (1989) Plasminogen activators in (pre)malignant conditions of the colorectum. Eur J Cancer Clin Oncol 25565-569
65. Wang SN, Miyauchi M, Koshikawa N, Maruyama K, Kubota T, Miura K, Kurosawa Y, Awaya A, Kanai Y (1994) Antigen expression associated with lymph node metastasis in gastric adenocarcinoma. Pathology Int 44: 844-849
66. Yonemura Y, Ninomiya I, Nojima N, Sugiyama K, Fujimura T, Tsuchihara K, Kawamura T, Kaji M, Miyazaki 1, Endo Y, Tanaka M, Sasaki T (1994) Prognostic value of urokinase-type plasminogen activators in gastric cancer. Oncol Rep 1: 765-772